Rolando I. Passi-Castillo

Santiago, RM 7610658, Chile

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for Psychosis.

Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for Psychosis.

Journal: Schizophrenia bulletin open

Published: December 20, 2025

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Journal: Schizophrenia bulletin open

Published: August 27, 2025

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.

Journal: Schizophrenia bulletin open

Published: August 27, 2025

Peripheral BDNF Levels in Individuals at Ultra-High Risk for Psychosis: A Systematic Review.

Peripheral BDNF Levels in Individuals at Ultra-High Risk for Psychosis: A Systematic Review.

Journal: Brain sciences

Published: July 31, 2025

Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.

Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.

Journal: Schizophrenia bulletin

Published: March 26, 2025

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

Journal: Schizophrenia (Heidelberg, Germany)

Published: October 29, 2024

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Journal: Schizophrenia (Heidelberg, Germany)

Published: August 28, 2024

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Journal: Schizophrenia bulletin

Published: March 07, 2024

Lifetime prevalence of psychotic-like experiences and associated factors in Chile.

Lifetime prevalence of psychotic-like experiences and associated factors in Chile.

Journal: Social psychiatry and psychiatric epidemiology

Published: March 07, 2024

Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive impairment in early stages of psychosis.

Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive impairment in early stages of psychosis.

Journal: Schizophrenia research. Cognition

Published: September 28, 2023

Cancer History Is Associated with Slower Speed of Cognitive Decline in Patients with Amnestic Cognitive Impairment.

Cancer History Is Associated with Slower Speed of Cognitive Decline in Patients with Amnestic Cognitive Impairment.

Journal: Journal of Alzheimer's disease : JAD

Published: May 02, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026